FDC Ltd. AI Stock Analysis
Want to see IN:FDC full AI Analyst Report?
FDC Ltd. (FDC) AI Stock Analysis
FDC Ltd.
(NSE:FDC)
FDC earns a moderate score. Its greatest strength is a virtually debt-free balance sheet with consistently growing equity and assets, supported by steady mid-single-digit revenue growth. However, profitability has eroded meaningfully — net margins have nearly halved since FY2021 — and free cash flow is projected to fall sharply in FY2026, raising questions about capital allocation. Technicals are the main near-term drag, with the stock below all key moving averages and negative MACD momentum, although oversold RSI and Stochastic readings suggest downside may be stretched. Valuation at ~19x earnings with a 1.4% yield is fair rather than compelling, leaving the shares fundamentally sound but lacking near-term catalysts.
FDC Ltd. (FDC) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 60.35B
- Dividend Yield
- 1.32%
- Average Volume (3M)
- 11.58K
- Price to Earnings (P/E)
- 19.5
- Beta (1Y)
- 0.75
- Revenue Growth
- 10.20%
- EPS Growth
- 38.95%
- Country
- India
- Employees
- 7,076
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
FDC Ltd. Business Overview & Revenue Model
Company Description
FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments, including anti-infectiv...
How the Company Makes Money
FDC makes money primarily by selling pharmaceutical and healthcare products. Revenue is generated from (1) sales of prescription medicines supplied to healthcare providers, hospitals, and pharmacies, and (2) sales of other healthcare products sold th...
FDC Ltd. Financial Statement Overview
Summary
A fortress balance sheet (score 85) anchors the profile — debt of just ₹212M against ₹22.8B equity (D/E under 1%), steadily rising assets and equity. The income statement (62) shows consistent revenue growth from ₹13.3B (FY2021) to ₹21.1B (FY2025) with ₹21.7B projected for FY2026, but net margins have roughly halved from ~23% to ~13% and EBITDA margins compressed from ~32% to ~20%. Cash flow (58) is the weakest link: FY2025 operating cash flow was strong at ₹3.64B with ~1.0x conversion of net income, yet free cash flow is projected to fall sharply to ₹623M in FY2026, pointing to heavy capex or working capital absorption.
Income Statement
62PositiveBalance Sheet
85Very PositiveCash Flow
58Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 22.89B | 21.71B | 21.08B | 19.35B | 17.84B | 15.26B |
| Gross Profit | 9.74B | 9.18B | 8.36B | 6.51B | 11.28B | 9.78B |
| EBITDA | 3.79B | 4.39B | 4.15B | 4.40B | 3.01B | 3.30B |
| Net Income | 3.13B | 2.81B | 2.67B | 3.05B | 1.94B | 2.16B |
Balance Sheet | ||||||
| Total Assets | 31.76B | 29.19B | 27.14B | 24.68B | 23.43B | 22.70B |
| Cash, Cash Equivalents and Short-Term Investments | 6.22B | 5.23B | 5.37B | 4.75B | 4.84B | 5.39B |
| Total Debt | 128.20M | 154.65M | 211.68M | 205.19M | 283.20M | 322.04M |
| Total Liabilities | 5.07B | 4.34B | 4.33B | 3.71B | 3.62B | 3.14B |
| Stockholders Equity | 26.69B | 24.85B | 22.81B | 20.97B | 19.82B | 19.57B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 622.92M | 2.67B | 1.27B | 418.21M | 291.08M |
| Operating Cash Flow | 0 | 2.49B | 3.64B | 2.21B | 1.55B | 1.62B |
| Investing Cash Flow | 0 | -1.59B | -2.47B | -170.83M | 111.35M | -1.45B |
| Financing Cash Flow | 0 | -925.39M | -913.47M | -2.02B | -1.80B | -98.37M |
FDC Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:FDC, the sentiment is Positive. The current price of 376.85 is above the 20-day moving average (MA) of 372.03, above the 50-day MA of 355.35, and above the 200-day MA of 370.67, indicating a bullish trend. The MACD of 9.06 indicates Positive momentum. The RSI at 54.77 is Neutral, neither overbought nor oversold. The STOCH value of 24.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:FDC.
FDC Ltd. Peers Comparison
Overall Rating
IN:STAR77Outperform
IN:BLISSGVS65Neutral
IN:FDC60Neutral
IN:ORCHPHARMA54Neutral
IN:UNICHEMLAB51Neutral
IN:INDOCO50Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 77Outperform | INR 90.65B | 14.68 | ― | 0.51% | 11.28% | 55.18% | |
| 65Neutral | INR 70.10B | 43.41 | ― | 0.23% | 24.87% | 46.37% | |
| 60Neutral | INR 61.35B | 19.54 | ― | 1.32% | 10.20% | 38.95% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 54Neutral | INR 55.82B | 544.36 | ― | ― | 10.83% | -89.83% | |
| 51Neutral | INR 33.90B | 10.00 | ― | ― | 6.44% | 283.10% | |
| 50Neutral | INR 20.73B | 66.15 | ― | 0.09% | 10.75% | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:FDC | FDC Ltd. | 376.85 | -28.54 | -7.04% | |
| IN:BLISSGVS | Bliss Gvs Pharma Limited | 659.25 | 499.06 | 311.55% | |
| IN:INDOCO | Indoco Remedies Limited | 224.60 | -37.87 | -14.43% | |
| IN:ORCHPHARMA | Orchid Pharma Limited | 932.20 | 82.35 | 9.69% | |
| IN:STAR | Strides Pharma Science Ltd | 983.45 | 26.73 | 2.79% | |
| IN:UNICHEMLAB | Unichem Laboratories Limited | 481.45 | 0.00 | 0.00% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 28, 2026
